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Abstract
Background: Hypertension is the prime risk factor for stroke, and primary aldosteronism (PA) is the most common
cause of secondary hypertension. The prevalence of PA in stroke patients has never been reported. The aim of this
study was to elucidate the prevalence of PA.
Methods: A total of 427 consecutive patients with acute stroke were prospectively enrolled for this study. The
screening tests were performed at the initial visit and a week after admission by measuring plasma aldosterone
concentration and plasma renin activity. The rapid adrenocorticotropic hormone (ACTH) test was performed as the
confirmatory test when both screening tests were positive. The primary endpoint was a final diagnosis of PA.
Results: The sensitivity of the dual screening system for the diagnosis of PA was 88.2 %, and PA was finally
diagnosed in 4.0 % of acute stroke patients and in 4.9 % of stroke patients with a history of hypertension. Patients
with PA were less likely to be male and have diabetes, and they had higher blood pressure at the initial visit, lower
potassium concentration, and more intracerebral hemorrhage. The rapid ACTH test was performed safely even in
acute stroke patients.
Conclusions: The prevalence of PA is not low among acute stroke patients. Efficient screening of PA should be
performed particularly for patients with risk factors.
Trial registration: UMIN-CTR; UMIN000011021. Trial registration date: June 23, 2013 (retrospectively registered).
Keywords: Stroke, Primary aldosteronism, Secondary hypertension, Risk factor, Intracranial hemorrhage, Ischemic
stroke
Background
Hypertension is the prime risk factor for stroke [1], and
treatment of hypertension is highly effective in the pre-
vention of stroke [2, 3]. Secondary hypertension is iden-
tified in a relatively small proportion of adult patients
with hypertension. However, particular attention should
be paid to this condition, because the hypertension can
be cured by appropriate specific treatment. Primary al-
dosteronism (PA) is caused by the autonomous secretion
of aldosterone from adrenocortical lesions and is associ-
ated with hypertension and hypokalemia. PA has
attracted much attention in recent years because PA is
more frequent than previously recognized, occurring in
3–10 % of hypertensive patients [4–6]. PA patients have
a higher rate of vascular complications [7, 8] and a
poorer long-term prognosis than patients with essential
hypertension [9]. Interestingly, the occurrence of ce-
rebrovascular comorbidities in patients with PA is
reported to be independent of hypertension and hypo-
kalemia [8, 10]. Therefore, aside from vascular injury
due to hypertension, the direct action of aldosterone on
the mineralocorticoid receptor may cause increased
oxidative stress and collagen remodeling, which results
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in endothelial dysfunction and fibrosis in the blood
vessels [11].
Most PA patients are successfully treated by unilateral
adrenalectomy or with mineralocorticoid receptor antago-
nists [12, 13], and the blood pressure becomes normalized
[14, 15]. Furthermore, some reports have demonstrated
improvement of left ventricular hypertrophy, renal func-
tion, and the cardiovascular prognosis with PA treatment
[16–18].
Although early diagnosis and treatment of PA are im-
portant for these reasons, stroke patients are not in-
cluded among the subjects for aggressive PA screening
in the guidelines [12, 13, 19], and there have been no
previous reports about the screening of PA in patients
with acute stroke. The aim of this prospective study was
to elucidate the prevalence and risk factors of PA in pa-
tients with acute stroke.
Methods
Study population
Consecutive patients with acute stroke including transi-
ent ischemic attack (TIA) who were admitted to Yoko-
hama Sakae Kyosai Hospital between April 2013 and
March 2014 were prospectively enrolled for this study.
The definition for “acute stroke inpatient” in this study
was “emergency admission” and “the requirement of
acute management of stroke”. The time from the onset
of stroke to admission was 0.6 ± 1.1 days (mean ± SD;
range, 0–6; median, 0). In addition to clinical evaluation,
including a history of vascular risk factors, all patients
underwent brain computed tomography and/or mag-
netic resonance imaging, chest X-ray, electrocardiog-
raphy, and standard blood tests. The vascular risk
factors examined were hypertension, diabetes mellitus,
dyslipidemia, history of smoking, and habitual drinking.
The Trial of Org 10172 in Acute Stroke Treatment cri-
teria were used for the classification of ischemic stroke
[20]. TIA was defined as a transient episode of neuro-
logical dysfunction without evidence of acute cerebral
infarction on neuroimaging [21].
The study was done in accordance with the principles
of the Helsinki declaration and was approved by The
Ethics Committee of Yokohama Sakae Kyosai Hospital
(approval number: 2013041601). Written informed con-
sent was obtained from all patients in compliance with
the committee’s requirements. This study was registered
with the University Hospital Medical Information Net-
work Clinical Trials Registry (UMIN-CTR, identifier:
UMIN000011021).
Screening test
For the screening of PA, plasma aldosterone concentra-
tion (PAC) and plasma renin activity (PRA) were mea-
sured simultaneously, and the PAC to PRA ratio (ARR)
was calculated, as previously described [22]. The criteria
for a positive screening test for PA were ARR ≥200 and
PAC ≥12 ng/dL [13]. The screening tests were per-
formed twice at the initial visit and about a week after
the admission, and the confirmatory test was performed
when both screening tests were positive. Although pa-
tients who were positive only on a single screening test
were in principle excluded from the confirmatory test,
exceptions were made for some patients because of the
potential effect of prehospital use or new administration
of antihypertensive drugs.
Confirmatory test
The rapid adrenocorticotropic hormone (ACTH) test
was performed as the confirmatory test, and patients
with a positive result were given the definitive diagnosis
of PA. The mechanism of the rapid ACTH test is con-
firmation of the hyperactivation of aldosterone by
ACTH stimulation in cases with aldosterone hypersecre-
tion [23]. The test was performed as follows. The patient
was asked to lie on a bed in the supine position for
30 min in the morning fasting state, and blood samples
were collected 30 and 60 min after the intravenous in-
jection of 0.25 mg ACTH. If the ratio of the maximal
PAC to the simultaneously-measured cortisol was ≥8.5,
PA was diagnosed [24]. The primary endpoint was a
final diagnosis of PA.
Statistical analysis
Data were analyzed with the use of Excel (version 2010;
Microsoft Corp, Redmond, WA) and Dr. SPSS II (SPSS
Inc, Chicago, IL). Demographic characteristics were
compared using Mann-Whitney’s U-test for continuous
variables, and the Chi-square test or Fisher’s exact test
for categorical variables. The differences were considered
significant with a P value <0.05.
Results
Patients’ baseline characteristics
A total of 427 patients with acute stroke were enrolled
during the study period. No patients were diagnosed
with PA before admission. The demographic characteris-
tics of the patients are shown in Table 1. The mean age
was 74.3 ± 11.9 years, and 56.7 % of the patients were
male. Hypertension was recognized in 67.4 % of the pa-
tients, and 55.3 % were treated with antihypertensive
drugs. The mean blood pressure at the initial visit was
162.8 ± 31.6/89.7 ± 20.2 mmHg. The subtypes of stroke
were: ischemic stroke (60.0 %), intracerebral hemorrhage
(24.8 %), subarachnoid hemorrhage (8.9 %), and TIA
(6.3 %). The study flow chart is shown in Fig. 1.
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Screening test
The initial screening test was performed in 401 patients;
it was not completed in 26 patients due to failure to
sample PAC and PRA (Fig. 1). The follow-up screening
test was not performed in 28 more patients because they
were discharged or transferred from our hospital or died
before the test. The follow-up screening test was per-
formed in a total of 373 patients, 6.8 ± 3.5 days after the
hospitalization on average. The initial and follow-up
screening tests were positive in 67 patients (18.0 %) and
32 patients (8.6 %), respectively. All of the 17 patients
with positive results on both screening tests underwent
the confirmatory test. There were 15 patients with a
negative initial test and a positive follow-up test, and 7
of them underwent the confirmatory test because they
might have been false-negative on initial screening due
to the prehospital use of antihypertensives. There were
50 patients with a positive initial test and a negative
follow-up test, and 5 of them underwent the confirma-
tory test because they might have been false-negative on
the follow-up screening due to the start of antihyperten-
sives after admission. A total of 291 patients (78.0 %)
showed negative results on both tests.
Confirmatory test
A total of 29 patients underwent the confirmatory test.
Fifteen of the 17 patients (88.2 %) with positive results
on both screening tests showed a positive result on the
confirmatory test. Two of 7 patients (28.6 %) with a
negative initial test and a positive follow-up test and
none of the five (0.0 %) patients with a positive initial
test and a negative follow-up test showed positive results
Table 1 Patients’ demographic characteristics
All patients Patients P value
with PA without PA
(n = 427) (n = 17) (n = 356)
Age, y 74.3 ± 11.9 70.6 ± 10.3 74.6 ± 11.8 0.095a
Male 242 (56.7 %) 5 (29.4 %) 212 (59.6 %)d 0.014b
Hypertension 288 (67.4 %) 14 (82.4 %) 245 (68.8 %) 0.237b
Diabetes 75 (17.6 %) 0 (0 %) 70 (19.6 %)d 0.027c
Dyslipidemia 120 (28.1 %) 3 (17.6 %) 104 (29.2 %) 0.230c
History of smoking 122 (28.6 %) 2 (11.8 %) 108 (30.3 %) 0.101b
Habitual drinking 140 (32.8 %) 4 (23.5 %) 125 (35.1 %) 0.327b
Initial systolic blood pressure, mmHg 162.8 ± 31.6 179.9 ± 26.1d 162.0 ± 31.6 0.012a
Initial diastolic blood pressure, mmHg 89.7 ± 20.2 101.8 ± 15.7d 89.2 ± 20.3 0.003a
Potassium, mmol/L 4.1 ± 1.1 3.7 ± 0.4 4.1 ± 0.5d 0.001a
Stroke subtypes
Ischemic stroke 256 (60.0 %) 7 (41.2 %) 225 (63.2 %) 0.067b
Large artery atherosclerosis 69 (16.2 %) 1 (5.9 %) 62 (17.4 %) 0.185c
Cardioembolism 93 (21.8 %) 3 (17.6 %) 81 (22.8 %) 0.443c
Small vessel occlusion 38 (8.9 %) 0 (0 %) 34 (9.6 %) 0.190c
Undetermined pathogenesis 56 (13.1 %) 3 (17.6 %) 48 (13.5 %) 0.418c
Intracerebral hemorrhage 106 (24.8 %) 8 (47.1 %)d 86 (24.2 %) 0.038c
Subarachnoid hemorrhage 38 (8.9 %) 0 (0 %) 24 (6.7 %) 0.315c
Transient ischemic attack 27 (6.3 %) 2 (11.8 %) 21 (5.9 %) 0.282c
Antihypertensive medication 236 (55.3 %) 9 (52.9 %) 203 (57.0 %) 0.740b
Calcium antagonist 166 (38.9 %) 9 (52.9 %) 134 (37.6 %) 0.233b
ARB / ACEI 123 (28.8 %) 2 (11.8 %) 87 (24.4 %) 0.101b
Direct renin inhibitor 1 (0.2 %) 0 (0 %) 1 (0.3 %) 0.954c
Diuretic 63 (14.8 %) 1 (5.9 %) 45 (12.6 %) 0.227c
Beta blocker 44 (10.3 %) 0 (0 %) 24 (6.7 %) 0.132c
Others 8 (1.9 %) 0 (0 %) 7 (2.0 %) 0.754c
Values in the table are means ± SD or Nos (%)
Abbreviations: ARB angiotensin receptor blocker; ACEI angiotensin-converting enzyme inhibitor
P value calculated by aMann-Whitney’s U-test, bChi-square test, or cFisher’s exact test. dindicates significantly higher or more frequent
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on the confirmatory test. No adverse events were ob-
served in relation to the confirmatory test using intra-
venous injection of ACTH.
Prevalence of primary aldosteronism in patients with
acute stroke
Seventeen patients (14 with a history of hypertension)
were finally diagnosed with PA, and they constituted
4.0 % of the total participants and 4.9 % of the patients
with a history of hypertension. Among the 373 patients
who underwent both screening tests, the prevalence of
PA was 4.6 % of the total and 5.5 % of the hypertensive
patients.
Characteristics of stroke patients with primary
aldosteronism
The demographic characteristics of the patients with
and without PA are shown in Table 1. The patients with
PA included fewer males (P = 0.014) and fewer with dia-
betes (P = 0.027), and they had higher blood pressure at
the initial visit (systolic P = 0.012, diastolic P = 0.003),
lower potassium concentration (P = 0.001), and more in-
tracerebral hemorrhage (P = 0.038). Although we found
no significant differences in ischemic stroke subtypes be-
tween patients with and without PA, all cardioembolic
strokes were based on non-valvular atrial fibrillation and
the culprit artery for atherothrombotic stroke was the
internal carotid artery in PA patients. The topographies
of hemorrhages in patients with PA were thalamus for 5
patients, and putamen, pons, and cerebellum for each
one of the remaining 3 patients. The mechanism of
hemorrhagic stroke in all PA patients was hypertensive
intracerebral hemorrhage. Only 5 patients (29.4 %) had
potassium concentrations below the lower limit of nor-
mal (3.5 mmol/L).
Discussion
In the present study, the prevalence rate of PA in pa-
tients with acute stroke was 4.0 % of all patients and
4.9 % of patients with hypertension, which is comparable
to that in previous reports of 3–10 % in the general
hypertensive population [4–6]. This study clearly dem-
onstrated for the first time that the rate of PA among
stroke patients is considerable, which has not been de-
scribed previously. However, this prevalence rate is likely
to be an underestimate, because confirmatory tests ne-
cessary for the definite diagnosis of PA were not per-
formed in all 82 patients who were positive on at least
one screening test. Therefore, the real prevalence rate of
PA in stroke patients might be higher than that reported
in this study.
The ARR of the screening tests may be easily affected
by various factors, especially in stroke patients. A false-
positive ARR elevation at the initial blood sampling
might be caused by the elevation of PRA and PAC due
to dehydration and by the decrease of PRA due to high
blood pressure in the acute stroke phase. Therefore,
confirmatory tests were not done when initial positive
and follow-up negative results were obtained on the
screening tests. However, the confirmatory test was per-
formed in 5 patients (Fig. 1) who were administered an-
tihypertensive agents after the stroke because such
treatment may decrease ARR and lead to a false-
negative result on the follow-up test. However, none of
these patients (0.0 %) were finally diagnosed with PA.
As for the interpretation of initial negative and follow-up
positive results on the screening tests, a false-negative result
might have been due to prehospital administration of anti-
hypertensive agents, and a false-positive ARR elevation on
the follow-up screening test might have been caused by the
effect of stopping or switching antihypertensive drugs after
Fig. 1 Flow chart of the study population
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the stroke. Therefore, 7 patients who fit the above
situation were selected, and the confirmatory test was
performed (Fig. 1); of these, 2 patients (28.6 %) were
diagnosed with PA.
Of the 17 patients with positive results on the initial
and follow-up screening tests, 15 (88.2 %) were diag-
nosed with PA (Fig. 1), suggesting that dual-positive re-
sults on two screening tests are highly reliable as
compared to a single-positive result (0.0 % and 28.6 %
on initial and follow-up tests, respectively), which is con-
sistent with the recommendation of the dual screening
system in the guidelines [13, 19]. The initial screening
test was less reliable than the follow-up test, thus the
first test might be better to be performed later than at
the first visit. However, we have no data to verify this
speculation. Because the confirmatory test for the defini-
tive diagnosis of PA needs the test drug (ACTH) and
more sets of laboratory tests, we believe the dual screen-
ing system may be easy and cost-effective to perform in
acute phase of stroke.
Screening tests for PA are recommended as much as
possible for all patients with hypertension [13]. Because
patients presenting with PA are reported to have a
higher frequency of cerebrovascular events than patients
with essential hypertension [8], it is important to not
overlook treatable PA for the prevention of recurrence
in stroke patients. However, several limitations should
also be taken into account when screening for PA in
stroke patients. First, the strict screening protocol, such
as cessation of antihypertensive drugs [13], cannot be
applied to stroke patients because treatment for stroke
in the acute phase has a higher priority than the diagno-
sis of PA. Second, the older age and the low level of ac-
tivities of daily living in stroke patients generally make it
difficult to perform adrenalectomy even if the diagnosis
of PA were made. In fact, the 17 patients diagnosed with
PA in the present study neither underwent invasive ad-
renal venous sampling for the subtype and localization
diagnosis nor adrenalectomy due to the reasons de-
scribed above or the patients’ refusal of further examin-
ation. Third, the cost-effectiveness of the screening for
PA in all stroke patients should also be considered.
Considering these special circumstances in stroke pa-
tients, intensive screening would be realistic in younger
patients at high risk for PA. The results of the present
study demonstrated that female sex, absence of diabetes,
high blood pressure at the initial visit (including poorly-
controlled blood pressure), lower potassium level, and
intracerebral hemorrhage were the risk factors for PA
(Table 1). Although small vessel occlusion is most re-
lated to hypertension among ischemic strokes [25], we
found no PA patients with this subtype. This result ei-
ther may be incidental, or may indicate that the effect of
PA on the occurrence of ischemic stroke largely depends
on the direct action of aldosterone on the mineralocor-
ticoid receptor.
We emphasize that it is important to recognize the
high prevalence of PA in stroke patients and that inten-
sive and efficient screening should be performed in pa-
tients with several of the risk factors for PA identified in
this study.
Conclusions
In acute stroke, PA was diagnosed in 4.0 % of total pa-
tients and in 4.9 % of patients with a history of hyper-
tension. In screening for PA, a dual screening system
including initial and follow-up tests seemed reliable
compared to a single screening system, because 88.2 %
of patients positive on both tests were confirmed to have
PA. The rapid ACTH test for the confirmation of PA
was performed safely. It is important to pay more atten-
tion to the possibility of the existence of PA in acute
stroke patients, and efficient screening of PA should be
performed particularly for young patients, considering
the risk factors clarified in this study.
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